


# Sultanate of Oman

Ministry of Health

Directorate General of Pharmaceutical Affairs  
and Drug Control

MUSCAT



سلطنة عمان  
وزارة الصحة  
المديرية العامة للصيدلانية  
والرقابة الدوائية  
مسقط

To:

**THE DIRECTOR GENERAL OF HEALTH SERVICES IN ALL GOVERNORATES**

Commanding Officer, Armed Forces Hospital (Al Khoudh & Salalah)

Director General of Engineering Affairs, MOH

Director General of Royal Hospital

Director General of Khoula Hospital

Director General of Medical Supplies (MOH)

Director General of Pvt. Health Est. Affairs (to kindly arrange distribution to all Pvt. Hospitals)

Hospital Director (Al Nahda Hospital)

Hospital Director (Al Massara Hospital)

The Head of Medical Services in SQU Hospital

The Head of Medical Services in Royal Oman Police

The Head of Medical Services in Ministry of Defence

The Head of Medical Services in The Diwan

The Head of Medical Services in The Sultan's Special Force

The Head of Medical Services in Internal Security Services

The Head of Medical Services in Petroleum Development of Oman

The Head of Medical Services in LNG Oman

**ALL PRIVATE PHARMACIES & DRUG STORES**

After Compliments,

Please find attached our Circular No. **71**..... dated **26/3/12**..... Regarding recall of Dimension Total Bilirubin (TBI) Flex reagent cartridge from Siemens Healthcare Diagnostics

Copy to:

- Director, Office of H.E. The Undersecretary for Health Affairs
- Director of Medical Device Control, DGPA&DC
- Director of Pharmacovigilance & Drug Information Dept, DGPA&DC
- Director of Drug Control Department, DGPA&DC
- Director of Pharmaceutical Licensing Department, DGPA&DC
- Director of Central Quality Control Lab., DGPA&DC
- Supdt. of Central Drug Information


# Sultanate of Oman

Ministry of Health

Directorate General of Pharmaceutical Affairs

and Drug Control

MUSCAT



سلطنة عمان  
وزارة الصحة  
المديرية العامة للأدوية  
والرقابة الدوائية  
مسقط

Circular No. 71 / 2020

01-81441 H

26 -3-2020

Ref: 52/2020

## Recall of Dimension Total Bilirubin (TBI) Flex reagent cartridge from Siemens Healthcare Diagnostics

Source of Recall	<a href="https://ncmdr.sfda.gov.sa/Secure/CA/CaViewRecall.aspx?caid=10&amp;rid=15112">https://ncmdr.sfda.gov.sa/Secure/CA/CaViewRecall.aspx?caid=10&amp;rid=15112</a>
Product	Dimension Total Bilirubin (TBI) Flex reagent cartridge-IVDs
Manufacturer	Siemens Healthcare Diagnostics
Local Agent	New Source
The affected products	Test Code: TBI Catalogue Number: DF167 Siemens Material Number: 10444957 All Lot Numbers
Reason for Recall	Siemens Healthcare Diagnostics has become aware that the United Kingdom Medicines and Healthcare products Regulatory Agency published an alert to healthcare professionals informing them that laboratory tests for bilirubin should be monitored for patients who take the drug eltrombopag due to the potential for discordant results. Eltrombopag may be used in the treatment of thrombocytopenia and/or aplastic anaemia. Siemens spiking studies have shown a positive bias in Total Bilirubin (TBI) results at a therapeutic concentration of eltrombopag. Interference has not been observed with the Direct Bilirubin (DBI) assay
Action	Healthcare is advising that for patients on eltrombopag therapy, use of Dimension TBI is not recommended. Siemens Healthcare advises that the Instructions For Use for the Dimension TBI assay will be updated as appropriate. The "Limitations of the Procedure" section in the Instructions For Use (IFU) for the Dimension TBI assay will be updated to indicate: "Use of this assay is not recommended for patients undergoing treatment with eltrombopag due to the potential for falsely elevated results". Siemens will provide further communication once the IFUs have been updated. Siemens is not recommending a review of previously generated results
comments	Healthcare professionals are encouraged to report any adverse events Suspected to be associated with the above device or any other medical Device to Director of Medical Device Control contact E-mail: <a href="mailto:Med-device@moh.gov.om">Med-device@moh.gov.om</a>

Directorate General of Pharmaceutical Affairs & Drug Control  
Sultanate of Oman

Dr. Mohammed Hamdan Al Rubaie

DIRECTOR GENERAL

